within Pharmacolibrary.Drugs.ATC.L;

model L04AB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.006333333333333333,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor alpha (TNF-Î±). It is used in the treatment of several autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Infliximab is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients with rheumatoid arthritis, Crohn's disease, and other autoimmune diseases. Typical parameters are for adults (males and females) with standard IV dosing regimens.</p><h4>References</h4><ol><li>Amy Hemperly, Niels Vande Casteele,Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.,Clinical pharmacokinetics,2018<a href='https://pubmed.ncbi.nlm.nih.gov/29330783/'>https://pubmed.ncbi.nlm.nih.gov/29330783/</a></li><li>Nicolas Williet, Stephane Paul, Laurent Peyrin-Biroulet, Xavier Roblin,Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.,Digestive diseases and sciences,2016<a href='https://pubmed.ncbi.nlm.nih.gov/26669880/'>https://pubmed.ncbi.nlm.nih.gov/26669880/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AB02;
